Adenovirus prime, Env protein boost vaccine protects against neutralization-resistant SIVsmE660 variants in rhesus monkeys

[1]  B. Pulendran,et al.  Signatures in Simian Immunodeficiency Virus SIVsmE660 Envelope gp120 Are Associated with Mucosal Transmission but Not Vaccination Breakthrough in Rhesus Macaques , 2015, Journal of Virology.

[2]  G. Learn,et al.  Breakthrough Virus Neutralization Resistance as a Correlate of Protection in a Nonhuman Primate Heterologous Simian Immunodeficiency Virus Vaccine Challenge Study , 2015, Journal of Virology.

[3]  H. Schuitemaker,et al.  Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys , 2015, Science.

[4]  J. Spouge,et al.  Conserved Molecular Signatures in gp120 Are Associated with the Genetic Bottleneck during Simian Immunodeficiency Virus (SIV), SIV-Human Immunodeficiency Virus (SHIV), and HIV Type 1 (HIV-1) Transmission , 2015, Journal of Virology.

[5]  Mario Roederer,et al.  Immunological and Virological Mechanisms of Vaccine-Mediated Protection Against SIV and HIV , 2013, Nature.

[6]  Holly Janes,et al.  Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. , 2013, The New England journal of medicine.

[7]  P. Gilbert,et al.  Sieve analysis in HIV-1 vaccine efficacy trials. , 2013, Current opinion in HIV and AIDS.

[8]  G. Learn,et al.  Heterogeneity in Neutralization Sensitivities of Viruses Comprising the Simian Immunodeficiency Virus SIVsmE660 Isolate and Vaccine Challenge Stock , 2013, Journal of Virology.

[9]  Christopher J. Miller,et al.  Comparative Characterization of Transfection- and Infection-Derived Simian Immunodeficiency Virus Challenge Stocks for In Vivo Nonhuman Primate Studies , 2013, Journal of Virology.

[10]  D. Montefiori,et al.  Protection Afforded by an HIV Vaccine Candidate in Macaques Depends on the Dose of SIVmac251 at Challenge Exposure , 2013, Journal of Virology.

[11]  Jerome H. Kim,et al.  Vaccine Protection Against Acquisition of Neutralization-Resistant SIV Challenges in Rhesus Monkeys , 2011, Nature.

[12]  M. Hudgens,et al.  Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys , 2011, Science Translational Medicine.

[13]  Matthew S. Lewis,et al.  Profound early control of highly pathogenic SIV by an effector-memory T cell vaccine , 2011, Nature.

[14]  B. Haynes,et al.  Low-Dose Mucosal Simian Immunodeficiency Virus Infection Restricts Early Replication Kinetics and Transmitted Virus Variants in Rhesus Monkeys , 2010, Journal of Virology.

[15]  B. Keele,et al.  Identifying and characterizing recently transmitted viruses , 2010, Current opinion in HIV and AIDS.

[16]  D. Montefiori,et al.  Breadth of Neutralizing Antibodies Elicited by Stable, Homogeneous Clade A and Clade C HIV-1 gp140 Envelope Trimers in Guinea Pigs , 2010, Journal of Virology.

[17]  J. Sodroski,et al.  TRIM5α Modulates Immunodeficiency Virus Control in Rhesus Monkeys , 2010, PLoS pathogens.

[18]  M. Hudgens,et al.  Assessing Vaccine Effects in Repeated Low‐Dose Challenge Experiments , 2009, Biometrics.

[19]  M. Hudgens,et al.  Power to detect the effects of HIV vaccination in repeated low-dose challenge experiments. , 2009, The Journal of infectious diseases.

[20]  Alan S. Perelson,et al.  Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1 , 2009, The Journal of experimental medicine.

[21]  D. Montefiori,et al.  Immune Control of an SIV Challenge by a T Cell-Based Vaccine in Rhesus Monkeys , 2008, Nature.

[22]  Hui Li,et al.  Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection , 2008, Proceedings of the National Academy of Sciences.

[23]  K. Mansfield,et al.  Magnitude and Phenotype of Cellular Immune Responses Elicited by Recombinant Adenovirus Vectors and Heterologous Prime-Boost Regimens in Rhesus Monkeys , 2008, Journal of Virology.

[24]  Z. Grossman,et al.  Progressive CD4+ central–memory T cell decline results in CD4+ effector–memory insufficiency and overt disease in chronic SIV infection , 2007, The Journal of Experimental Medicine.

[25]  Z. Grossman,et al.  The Journal of Experimental Medicine , 2000 .

[26]  K. Mansfield,et al.  Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors from Subgroups B and D , 2007, Journal of Virology.

[27]  D. Burton,et al.  Assorted Mutations in the Envelope Gene of Simian Immunodeficiency Virus Lead to Loss of Neutralization Resistance against Antibodies Representing a Broad Spectrum of Specificities , 2003, Journal of Virology.

[28]  R. Desrosiers,et al.  Importance of B-Cell Responses for Immunological Control of Variant Strains of Simian Immunodeficiency Virus , 2003, Journal of Virology.